SEC Tracker
Get the app
MIST · XBRL financial data

Milestone Pharmaceuticals financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (MIST's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Revenue——————————238559
Revenue from contracts with customers——————00——238559
Cost of goods and services sold——————00——1432
Research and development6,7215,452*3,6392,8153,9633,940*4,9783,6693,9405,521*3,2513,509
Selling, general and administrative———————8,862———22,648
General and administrative4,2273,371*3,9535,0463,7424,001*5,1673,7593,2635,085*4,824—
Operating income (loss)(15,360)(13,800)*(10,476)(9,662)(9,616)(12,348)*(20,523)(12,531)(11,829)(17,257)*(23,663)(25,630)
Interest income1,1201,046*9941,1861,080904*697516874833*1,7321,741
Interest expense841857*872887903919*935951967985*4,1354,725
Net income (loss)(15,081)(13,611)*(10,354)(9,363)(9,439)(12,363)*(20,761)(12,966)(11,922)(17,409)*(26,066)(28,614)
Earnings per share, basic USD per share(0.35)—(0.21)(0.14)(0.14)—(0.31)(0.20)(0.12)—(0.20)(0.21)
Earnings per share, diluted USD per share(0.35)—(0.21)(0.14)(0.14)—(0.31)(0.20)(0.12)—(0.20)(0.21)

Balance sheet

CSV

Fiscal quarters (MIST's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents9,87913,76010,13113,26212,79925,31445,08542,49946,68573,04671,317169,728
Short-term investments65,86752,24379,35069,99163,62044,38110,87391835,90032,914112,899881
Accounts receivable——————————1,6052,720
Inventory—————————6481,8264,722
Total current assets84,79773,03293,96787,35980,99073,92660,47546,16886,670111,921192,253180,327
Property and equipment, net272277249222201197176159136511500469
Right-of-use asset2,0471,9171,7851,6511,5151,3761,2341,0909441,129981829
Total assets87,11675,22696,00189,23282,70675,49961,88547,41787,750113,561193,734181,625
Accounts payable—————————5,64510,0238,454
Accrued liabilities—————————7,6449,80311,983
Total current liabilities8,1147,2264,1304,5675,2588,12612,9639,28310,52413,97920,94422,184
Lease liability, non-current1,5831,4571,3061,1561,002874758641519539366192
Total liabilities58,61258,45556,08057,25458,69462,35268,00865,16267,24971,792157,685163,407
Accumulated deficit(312,415)(326,026)(336,380)(345,743)(355,182)(367,545)(388,306)(401,272)(413,194)(430,603)(456,669)(485,283)
Total stockholders' equity28,50416,77139,92131,97824,01213,147(6,123)(17,745)20,50141,76936,04918,218
Total liabilities and equity87,11675,22696,00189,23282,70675,49961,88547,41787,750113,561193,734181,625
Common shares outstanding (cover page) thousands of shares33,48353,15053,26053,27053,32853,35453,46484,99485,169117,667124,498124,498

Cash flows

CSV

Fiscal quarters (MIST's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)(15,081)(13,611)*(10,354)(9,363)(9,439)(12,363)*(20,761)(12,966)(11,922)(17,409)*(26,066)(28,614)
Stock-based compensation2,872*1,877*1,5121,391*1,399*1,474*1,3511,308*1,250*3,552*1,2821,338*
Depreciation and amortization24*26*2826*25*26*2728*25*34*5657*
Net cash from operating activities(12,160)*(9,796)*(8,934)(6,053)*(7,018)*(6,843)*(13,952)(12,566)*(9,748)*(12,775)*(16,053)(22,714)*
Purchases of property and equipment18*31*——4*22*611*2*283*4526*
Net cash from investing activities(10,857)*13,676*(27,014)9,482*6,481*19,334*33,5839,944*(34,984)*2,703*(80,030)111,992*
Proceeds from issuing common stock——27,538(280)*0*0*———14,450*10,8900*
Net cash from financing activities305*1*32,319(298)*74*24*14036*48,918*36,433*94,3549,133*
Net change in cash(22,712)*3,881*(3,629)3,131*(463)*12,515*19,771(2,586)*4,186*26,361*(1,729)98,411*

Compare with peers

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
Milestone Pharmaceuticals169,728559(22,714)*124.5M7.5 quarters 10-QJun 30, 2026
Assembly Biosciences32,286not reported(15,488)*20.4M20.7 quarters 10-QJun 30, 2026
DiaMedica Therapeutics5,129not reported(8,114)*53.9M5.4 quarters 10-QJun 30, 2026
Ironwood Pharmaceuticals79,127113,04158,276*165.2M— 10-QJun 30, 2026
Vaxart50,92927,1852,778*242.8M— 10-QJun 30, 2026
Larimar Therapeutics92,687not reported(44,030)*103.9M3.5 quarters 10-QJun 30, 2026
Achieve Life Sciences47,958not reported(10,777)*102.9M17.4 quarters 10-QJun 30, 2026
Fennec Pharmaceuticals41,24917,87450*35.1M— 10-QJun 30, 2026
Atossa Therapeutics26,094not reported(9,644)*10.0M2.7 quarters 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.